All 2 tracked stories fall under one category: pharma. Namit Joshi is most often covered alongside Pharmexcil, which appears in 2 of these 2 stories. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline.
Coverage balanceBalanced directional read. Positive and negative coverage are within 0 percentage points.
50% positive
50% negative
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Namit Joshi
All 2 tracked stories fall under one category: pharma. Namit Joshi is most often covered alongside Pharmexcil, which appears in 2 of these 2 stories. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. The 6 average consequence score is above the beat benchmark of 5.9 in the same window. We currently track 2 Biotech stories that mention Namit Joshi, published between July 27, 2026 and August 1, 2026.
Stories tracked
2
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 50 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Namit Joshi. Shared-story counts are live from our verified record — not editorial picks.
The proposed US tariff on generic drugs—jumping to 200%—poses an existential threat to Indian pharmaceutical companies that have long dominated the American market. With margins razor-thin and a 4-5 year timeline needed to onshore production, industry leaders call the plan 'completely out of scope,' potentially forcing a major restructuring of global generic supply chains.
The zero-tariff India-UK trade pact propels Indian pharmaceutical exports to a projected $981M, offering biotech and pharma firms expanded market access, lower costs, and new collaboration channels in R&D and manufacturing.